AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23377391 — intervention group
Group type: COMPARATOR
Intervention: Proactiv
Number of subjects: 40
Study 23377391 — intervention group
Group type: COMPARATOR
Intervention: Murad
Number of subjects: 40
Study 25427324 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100000 epinephrine
Number of subjects: 33
Study 25427324 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100000 epinephrine
Number of subjects: 33
Study 25427324 — intervention group
Group type: COMPARATOR
Intervention: 2% mepivacaine with 1:100000 epinephrine
Number of subjects: 33
Study 19154279 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive addition lenses (PALs) with a near addition of +1.50 D
Number of subjects: 178
Study 19154279 — intervention group
Group type: COMPARATOR
Intervention: Single vision (SV) lenses
Number of subjects: 178
Study 19154279 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive addition lenses (PALs)
Number of subjects: 178
Study 17157387 — intervention group
Group type: EXPERIMENTAL
Intervention: Good Behavior Game intervention
Number of subjects: 448
Study 17157387 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 448
Study 15340332 — intervention group
Group type: EXPERIMENTAL
Intervention: Active intervention (multifactorial preventive interventions)
Number of subjects: 136
Study 15340332 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 136
Study 11938803 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese drugs (CD) for invigorating Spleen to remove dampness, activating blood circulation to eliminate Turbid
Number of subjects: 39
Study 11938803 — intervention group
Group type: COMPARATOR
Intervention: Control group (low protein diet and controlling blood pressure)
Number of subjects: 39
Study 8941030 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 100
Study 8941030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 1383924 — intervention group
Group type: EXPERIMENTAL
Intervention: MOP chemotherapy
Number of subjects: 152
Study 1383924 — intervention group
Group type: EXPERIMENTAL
Intervention: MOP followed by radiotherapy (RT)
Number of subjects: 152
Study 1383924 — intervention group
Group type: COMPARATOR
Intervention: MOP/ABVD chemotherapy
Number of subjects: 152
Study 1383924 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality therapy (CMT)
Number of subjects: 152
Study 3905463 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (2 mg/kg) in addition to routine insulin treatment
Number of subjects: 24
Study 3905463 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 24
Study 3905463 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated patients (remission group)
Number of subjects: 24
Study 31076875 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine agonists
Number of subjects: 131
Study 31076875 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 131
Study 31076875 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticholinergics
Number of subjects: 131
Study 31076875 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial treatment
Number of subjects: 131
Study 31076875 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa equivalent daily dose
Number of subjects: 131
Study 28651616 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynesys posterior dynamic stabilization (PDS)
Number of subjects: 56
Study 28651616 — intervention group
Group type: COMPARATOR
Intervention: Fusion
Number of subjects: 56
Study 28651616 — intervention group
Group type: EXPERIMENTAL
Intervention: PDS
Number of subjects: 56
Study 28651616 — intervention group
Group type: COMPARATOR
Intervention: Both groups (PDS and Fusion)
Number of subjects: 56
Study 25481367 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg caffeine
Number of subjects: 107
Study 25481367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 25481367 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy (response expectancy score)
Number of subjects: 107
Study 25481367 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine administration (conditional vs deceptive)
Number of subjects: 107
Study 23560727 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg twice daily for 1 week
Number of subjects: 63
Study 23560727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 21493022 — intervention group
Group type: COMPARATOR
Intervention: Estrogen therapy-control (ET-CO)
Number of subjects: 47
Study 21493022 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo-aerobic training (PLA-AT)
Number of subjects: 47
Study 21493022 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy-aerobic training (ET-AT)
Number of subjects: 47
Study 21493022 — intervention group
Group type: COMPARATOR
Intervention: Placebo-control (PLA-CO)
Number of subjects: 47
Study 19820441 — intervention group
Group type: COMPARATOR
Intervention: Natalizumab induction therapy (12 weeks)
Number of subjects: 2
Study 19820441 — intervention group
Group type: COMPARATOR
Intervention: Natalizumab maintenance therapy (48 weeks post-induction)
Number of subjects: 2
Study 17097449 — intervention group
Group type: EXPERIMENTAL
Intervention: StatLock securing device (experimental group)
Number of subjects: 118
Study 17097449 — intervention group
Group type: COMPARATOR
Intervention: Preexisting methods (control group including tape, Velcro strap, CathSecure, or none)
Number of subjects: 118
Study 14760156 — intervention group
Group type: COMPARATOR
Intervention: ASC only
Number of subjects: 840
Study 14760156 — intervention group
Group type: EXPERIMENTAL
Intervention: ASC+MVP (mitomycin, vinblastine, and cisplatin)
Number of subjects: 840
Study 14760156 — intervention group
Group type: EXPERIMENTAL
Intervention: ASC+N (vinorelbine)
Number of subjects: 840
Study 11497093 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia
Number of subjects: 17
Study 9336321 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal cocaine (100 mg)
Number of subjects: 8
Study 9336321 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of alcohol (0.8 g/kg) and cocaine (100 mg)
Number of subjects: 8
Study 9336321 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of alcohol and cocaine
Number of subjects: 8
Study 9336321 — intervention group
Group type: COMPARATOR
Intervention: Cocaine alone
Number of subjects: 8
Study 8402115 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstruction in the posterior mediastinum
Number of subjects: 96
Study 2879734 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil 15 mg i.v.
Number of subjects: 10
Study 2879734 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil 30 mg i.v.
Number of subjects: 10
Study 2879734 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 5 mg i.v. (positive control)
Number of subjects: 10
Study 3189211 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-calorie diet with 41% protein plus 55% carbohydrate (CD)
Number of subjects: 17
Study 3189211 — intervention group
Group type: COMPARATOR
Intervention: Very-low-calorie diet with 95% protein (PP)
Number of subjects: 17
Study 29313710 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-implemented goal-directed sedation protocol
Number of subjects: 1360
Study 29313710 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1360
Study 28399028 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparotomy
Number of subjects: 715
Study 28399028 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopy
Number of subjects: 715
Study 28399028 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy
Number of subjects: 715
Study 28399028 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intermediate risk criteria
Number of subjects: 715
Study 28399028 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk uterine factors
Number of subjects: 715
Study 26665553 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (1.25 mg/0.05 mL) alone
Number of subjects: 72
Study 26665553 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (Intravitreal bevacizumab + macular photocoagulation)
Number of subjects: 72
Study 26665553 — intervention group
Group type: COMPARATOR
Intervention: Macular photocoagulation alone
Number of subjects: 72
Study 23201024 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrolisthesis
Number of subjects: 125
Study 23201024 — intervention group
Group type: COMPARATOR
Intervention: Control (no retrolisthesis)
Number of subjects: 125
Study 21638037 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20
Study 21638037 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 17644263 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous transplantation of Matriderm and split-thickness skin grafting (STSG)
Number of subjects: 10
Study 17644263 — intervention group
Group type: COMPARATOR
Intervention: Split-thickness skin grafting (STSG) alone
Number of subjects: 10
Study 16545672 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery audiotape intervention used before surgery, after surgery, and after discharge from AS.
Number of subjects: 75
Study 16545672 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery audiotape intervention
Number of subjects: 75
Study 12927315 — intervention group
Group type: EXPERIMENTAL
Intervention: estradiol 2 mg/day + cyproterone acetate 1 mg/day in a cyclic sequential regimen
Number of subjects: 41
Study 12927315 — intervention group
Group type: EXPERIMENTAL
Intervention: estradiol hemihydrate 2 mg/day plus norethisterone acetate (NETA) 1 mg/day in a continuous combined regimen
Number of subjects: 41
Study 12927315 — intervention group
Group type: EXPERIMENTAL
Intervention: estradiol hemihydrate 1 mg/day plus NETA 0.5 mg/day in a continuous combined regimen
Number of subjects: 41
Study 11009230 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral mexiletine (up to 900 mg/d)
Number of subjects: 20
Study 11009230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8725471 — intervention group
Group type: EXPERIMENTAL
Intervention: EGb 761 (160 mg per day in two divided doses)
Number of subjects: 44
Study 1564114 — intervention group
Group type: EXPERIMENTAL
Intervention: Furlow cleft palate repair using a double opposing Z-plasty
Number of subjects: 10
Study 1564114 — intervention group
Group type: COMPARATOR
Intervention: von Langenbeck technique
Number of subjects: 10
Study 3932215 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (CTX)
Number of subjects: 46
Study 3932215 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin and gentamicin (C + Gen)
Number of subjects: 46
Study 3932215 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin, gentamicin and penicillin (C + Gen + P)
Number of subjects: 46
Study 3932215 — intervention group
Group type: COMPARATOR
Intervention: C + Gen
Number of subjects: 46
Study 3932215 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 46
Study 31898055 — intervention group
Group type: EXPERIMENTAL
Intervention: dlPFC tDCS
Number of subjects: 69
Study 31898055 — intervention group
Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 69
Study 30519483 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimorbidity exercise rehabilitation
Number of subjects: 17
Study 30519483 — intervention group
Group type: COMPARATOR
Intervention: Disease-specific exercise rehabilitation
Number of subjects: 17
Study 28404110 — intervention group
Group type: EXPERIMENTAL
Intervention: Ombitasvir (25 mg), paritaprevir (150 mg), ritonavir (100 mg) plus weight-based ribavirin for 12 weeks
Number of subjects: 160
Study 28404110 — intervention group
Group type: EXPERIMENTAL
Intervention: Ombitasvir, paritaprevir, ritonavir plus ribavirin for 12 weeks
Number of subjects: 160
Study 28404110 — intervention group
Group type: EXPERIMENTAL
Intervention: Ombitasvir, paritaprevir, ritonavir plus ribavirin for 24 weeks
Number of subjects: 160
Study 28404110 — intervention group
Group type: EXPERIMENTAL
Intervention: Ombitasvir, paritaprevir, ritonavir plus ribavirin
Number of subjects: 160
Study 24965536 — intervention group
Group type: EXPERIMENTAL
Intervention: Catumaxomab plus prednisolone (25 mg intravenous premedication)
Number of subjects: 0
Study 24965536 — intervention group
Group type: COMPARATOR
Intervention: Catumaxomab alone
Number of subjects: 0
Study 22692377 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ketamine (20 mg/h for 2 h)
Number of subjects: 12
Study 22692377 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ketamine
Number of subjects: 12
Study 22692377 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (pretreatment)
Number of subjects: 12
Study 22692377 — intervention group
Group type: COMPARATOR
Intervention: Placebo (pretreatment)
Number of subjects: 12
Study 20307268 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 0
Study 20307268 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 18506154 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe 10 mg daily (n = 29)
Number of subjects: 84
Study 18506154 — intervention group
Group type: EXPERIMENTAL
Intervention: AEGR-733 5.0 mg daily for the first 4 weeks, 7.5 mg daily for the second 4 weeks, and 10 mg daily for the last 4 weeks (n = 28)
Number of subjects: 84
Study 18506154 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg daily and AEGR-733 with dose titration (n = 28)
Number of subjects: 84
Study 15919463 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tacr)
Number of subjects: 84
Study 15919463 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CsA)
Number of subjects: 84
Study 15919463 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate Mofetil (MMF)
Number of subjects: 84
Study 15919463 — intervention group
Group type: COMPARATOR
Intervention: Aza (Azathioprine)
Number of subjects: 84
Study 11451757 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-diet (9.2 energy percent of trans fatty acids)
Number of subjects: 29
Study 11451757 — intervention group
Group type: COMPARATOR
Intervention: Sat-diet (saturated fatty acids)
Number of subjects: 29
Study 11451757 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-diet
Number of subjects: 29
Study 11451757 — intervention group
Group type: COMPARATOR
Intervention: Sat-diet
Number of subjects: 29
Study 9712245 — intervention group
Group type: COMPARATOR
Intervention: Intestinal sounds from healthy volunteers
Number of subjects: 12
Study 9712245 — intervention group
Group type: COMPARATOR
Intervention: Intestinal sounds from patients with intestinal obstruction
Number of subjects: 12
Study 9712245 — intervention group
Group type: COMPARATOR
Intervention: Bowel sounds from patients with peritonitis
Number of subjects: 12
Study 9712245 — intervention group
Group type: COMPARATOR
Intervention: Specialists in gastrointestinal medicine
Number of subjects: 12
Study 8005843 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg body weight)
Number of subjects: 6
Study 8005843 — intervention group
Group type: COMPARATOR
Intervention: Caffeine withdrawal (placebo)
Number of subjects: 6
Study 2916880 — intervention group
Group type: EXPERIMENTAL
Intervention: Food intake (meal)
Number of subjects: 36
Study 2916880 — intervention group
Group type: COMPARATOR
Intervention: Fasting (control group)
Number of subjects: 36
Study 31567605 — intervention group
Group type: EXPERIMENTAL
Intervention: Cable-driven gait trainer combined with conventional physiotherapy (n = 20)
Number of subjects: 40
Study 31567605 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy only (n = 20)
Number of subjects: 40
Study 28681744 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintained levodopa dose (Group 1, n = 66)
Number of subjects: 107
Study 28681744 — intervention group
Group type: COMPARATOR
Intervention: Reduced levodopa dose by 15-25% (Group 2, n = 41)
Number of subjects: 107
Study 28681744 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups after LCE administration
Number of subjects: 107
Study 28681744 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (safety population)
Number of subjects: 107
Study 23893534 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (5 minutes of vigorous activity)
Number of subjects: 0
Study 23893534 — intervention group
Group type: COMPARATOR
Intervention: Sedentary task (control group)
Number of subjects: 0
Study 23893534 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (Study 1)
Number of subjects: 0
Study 24366725 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine 0.5% (15 mg test dose + 50 mg)
Number of subjects: 93
Study 24366725 — intervention group
Group type: EXPERIMENTAL
Intervention: ADRB2 genotypes (Arg16Arg, Arg16Gly, Gly16Gly)
Number of subjects: 93
Study 24366725 — intervention group
Group type: EXPERIMENTAL
Intervention: ADRB2 genotypes (Gln27Gln, Gln27Glu, Glu27Glu)
Number of subjects: 93
Study 24366725 — intervention group
Group type: EXPERIMENTAL
Intervention: ADRB2 Glu27 allele
Number of subjects: 93
Study 23031632 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin cream (0.1) applied twice daily for 4 weeks
Number of subjects: 96
Study 23031632 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin cream (0.2) applied twice daily for 4 weeks
Number of subjects: 96
Study 23031632 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied twice daily for 4 weeks
Number of subjects: 96
Study 23031632 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 96
Study 20415160 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-controlled concurrent feedback
Number of subjects: 15
Study 20415160 — intervention group
Group type: EXPERIMENTAL
Intervention: Imposed concurrent feedback (yoked group)
Number of subjects: 15
Study 20415160 — intervention group
Group type: COMPARATOR
Intervention: No concurrent feedback (control group)
Number of subjects: 15
Study 17285318 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month Better Ageing structured group exercise programme
Number of subjects: 176
Study 17285318 — intervention group
Group type: EXPERIMENTAL
Intervention: Time spent sedentary (min/day)
Number of subjects: 176
Study 17285318 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative feedback from 27 research participants and 4 exercise leaders
Number of subjects: 176
Study 15356071 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (transdermal estradiol 50 microg and micronized progesterone 100 mg/d)
Number of subjects: 21
Study 15356071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 11594636 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training in group, twice a week for eight weeks
Number of subjects: 23
Study 11594636 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 23
Study 10909613 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA-enriched formula (Materna Premium)
Number of subjects: 50
Study 10909613 — intervention group
Group type: COMPARATOR
Intervention: Regular whey-predominant infant formula (Materna Plus)
Number of subjects: 50
Study 10909613 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 7734458 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine gradual detoxification (36 days; N = 3)
Number of subjects: 8
Study 7734458 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine rapid detoxification (12 days; N = 5)
Number of subjects: 8
Study 2675962 — intervention group
Group type: EXPERIMENTAL
Intervention: G + CS + CL
Number of subjects: 5
Study 2675962 — intervention group
Group type: EXPERIMENTAL
Intervention: G + CL
Number of subjects: 5
Study 2675962 — intervention group
Group type: EXPERIMENTAL
Intervention: G + CS + CO + CL
Number of subjects: 5
Study 2675962 — intervention group
Group type: COMPARATOR
Intervention: G
Number of subjects: 5
Study 31026331 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary care
Number of subjects: 129
Study 31026331 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 129
Study 28386739 — intervention group
Group type: EXPERIMENTAL
Intervention: Articaine 60 mg with fentanyl 10 µg (group AF10)
Number of subjects: 90
Study 28386739 — intervention group
Group type: EXPERIMENTAL
Intervention: Articaine 60 mg with fentanyl 20 µg (group AF20)
Number of subjects: 90
Study 28386739 — intervention group
Group type: COMPARATOR
Intervention: Plain articaine 60 mg with saline (group AF0)
Number of subjects: 90
Study 28386739 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 20 µg (group AF20)
Number of subjects: 90
Study 28386739 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study 25361738 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin treatment in Han patients
Number of subjects: 0
Study 25361738 — intervention group
Group type: EXPERIMENTAL
Intervention: SERPINC1 gene sequencing
Number of subjects: 0
Study 25361738 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of SERPINC1 SNP frequency
Number of subjects: 0
Study 23836249 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 80 mg tobramycin twice daily for 12 months
Number of subjects: 44
Study 23836249 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (placebo)
Number of subjects: 44
Study 21500267 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium-enhanced cardiac magnetic resonance imaging with T(1) mapping and correction for patient-specific factors.
Number of subjects: 0
Study 21500267 — intervention group
Group type: COMPARATOR
Intervention: Pre-correction T(1) values from normal subjects and type 1 diabetic patients.
Number of subjects: 0
Study 19470834 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH
Number of subjects: 42
Study 19470834 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP-2
Number of subjects: 42
Study 17229952 — intervention group
Group type: EXPERIMENTAL
Intervention: Early insertion of tympanostomy tubes
Number of subjects: 429
Study 17229952 — intervention group
Group type: COMPARATOR
Intervention: Delayed insertion of tympanostomy tubes
Number of subjects: 429
Study 15533901 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy intervention (two daily servings of soy foods containing approximately 50 mg of isoflavones)
Number of subjects: 220
Study 15533901 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintained regular diet)
Number of subjects: 220